VEA240920C57000
- 0.08
- 0.000.00%
Vanguard FTSE Developed Markets ETF Newsroom
Equity Funds Observed Outflows for the First Week in 21
Novartis Lower as BofA Downgrades on Risks to Valuation
VEA ETF Declines 0.4%
Novartis Licenses Gene Therapy Component From Voyager
Novartis Expands U.S. Radiopharma Production Amid Rising Competition
Siemens Healthineers Seeks €200M Novartis Deal to Boost Cancer Imaging Business: FT
Japan Equities Look Attractive After Sell-off and Carry Trade Fears - JPM
ETFs Pull in $127B in July, the Third-best Month Ever Recorded
Earnings Summary: Novartis Beats Q2 Earnings Estimates; Raises 2024 Profit Forecast on Demand for New Drugs
Novartis Beats Top-line and Bottom-line Estimates; Raises FY24 Core Operating Income Outlook
Top 10 ETF Inflow Leaders for June - Citi Research
Vanguard FTSE Developed Markets ETF To Go Ex-Dividend On June 21st, 2024 With 0.4607 USD Dividend Per Share
June 19th (Eastern Time) - $Vanguard FTSE Developed Markets ETF(VEA.US)$ is trading ex-dividend on June 21st, 2024.Shareholders of record on June 21st, 2024 will receive 0.4607 USD dividend per share
Citi Says ETFs Will Engulf U.S. Asset Management Industry
ECB Jumps Ahead of the Fed to Deliver Its First Rate Cut. Is Now a Good Time to Invest in Europe ETFs?
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations
Novartis, Roche Facing Italy Antitrust Probe Over Lucentis Biosimilar
China's Trade With DM Has Reduced; Increased With EM - SG
Travere Gains on Novartis Data for Filspari Rival, Calliditas Buyout
Marjorie Taylor Greene Reveals New Stock Trades After 2-Year Gap: Berkshire Hathway, Goldman Sachs And Microsoft Make The List — But Trump's DJT Doesn't
Radiopharma Stocks Higher as Sector Welcomes the Latest M&A Deal